2018 American Transplant Congress
Less Induction Therapy Means Fewer Early Readmissions with No Change in Rejection or Infection
Vanderbilt University Medical Center, Nashville, TN.
PURPOSE:In heart transplant, induction may allow for delay of calcineurin inhibitor initiation and renal recovery. Literature comparing lymphocyte-depleting and non-depleting induction conflicts in rejection rate…2018 American Transplant Congress
Adjusted Body Weight Dosing of Rabbit Antithymocyte Globulin in Obese Renal Transplant Recipients Preserves Excellent Clinical Outcomes at 3 Years and Improves the Value of Care
University of Virginia Health System, Charlottesville, VA.
There is significant variability in antithymocyte globulin (ATG) dosing practices among centers. In the obese population, use of total body weight (TBW) vs. adjusted body…2018 American Transplant Congress
Effect of Induction Therapy on CD4 Cell Count Recovery Following Renal Transplantation in HIV Positive Recipients – A Single Center Experience
Department of Transplantation, Mayo Clinic College of Medicine, Jacksonville, FL.
The feasibility, complications and outcomes of solid organ transplantation in the HIV positive population are well documented and have had excellent outcomes with a slight…2018 American Transplant Congress
Effect of rATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients
Beijing Chao-Yang Hospital, Beijing, China.
Myeloid-derived suppressor cells (MDSCs) consist of heterogeneous myeloid progenitors and precursors that was first defined in cancer patients and are characterized by a regulatory ability…2018 American Transplant Congress
Age Stratified Efficacy and Safety Outcomes of Induction Immunosuppression in Renal Transplantation
Purpose: Rejection and infection remain a leading concern for decreased graft survival after renal transplant (RT). Induction immunosuppression is associated with a decreased risk of…2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…2018 American Transplant Congress
Induction Type and Outcomes in HLA-DR Mismatch Kidney Transplantation
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch is considered high immunologic risk portending inferior outcomes. We sought to explore the impact of induction type used on…2018 American Transplant Congress
Successful Transplantation in a Sensitized Patient Allergic to Commercially Available Antibody Induction Agents
Antibody induction in renal transplantation has increased to over 80%. Rabbit anti-thymocyte globulin (rATG) is the most commonly used agent. Hypotension, rash, dyspnea with rATG…2018 American Transplant Congress
Deceased Donor Urinary Biomarker Signature and the Effectiveness of Peritransplant Lymphocyte Depletion on Early Renal Allograft Function
Purpose: Delayed graft function (DGF) is associated with increased allogaft immunogenicity and decreased long-term survival. We hypothesized that high levels of donor urinary biomarkers for…2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 31
- Next Page »